Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system, resulting in progressive muscle weakness and — ultimately — death. The disease ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Are you searching for effective medications to treat 'Amyotrophic Lateral Sclerosis (ALS)'? This comprehensive guide provides the latest information on medications-both generic and branded-that ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a ...

Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the development of effective treatments. Given these challenges ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Its lead product is NeuroNata-R (lenzumestrocel), the world’s first stem cell-based therapy for amyotrophic lateral sclerosis (ALS). NeuroNata-R was approved as an orphan drug for the treatment ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...